Drug‐Coated Balloon‐Based Treatment of Left Main True Bifurcation Lesion
- 22 January 2025
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
Abstract
Background: There is a paucity of data regarding drug‐coated balloon (DCB) treatment in the context of left main (LM) true bifurcation lesions.Aims: The aim of this study was to evaluate the safety and efficacy of DCB‐based treatment for unprotected LM true bifurcation lesions.Methods: A total of 39 patients with LM true bifurcation lesion (Medina: 1,1,1/0,1,1/1,0,1) who were successfully treated with DCB alone or in combination with drug‐eluting stent (DES) were retrospectively enrolled into the DCB‐based group. They were compared with 39 propensity‐matched patients who were treated with second‐generation DES from the COBIS III registry (n = 2648). Major adverse cardiovascular events (MACE) were defined as cardiac death, myocardial infarction, stent or target lesion thrombosis, and target lesion revascularization at the 2‐year follow‐up.Results: Baseline clinical characteristics were similar between the groups, except for the prevalence of in‐stent restenosis (ISR) lesions (41.0% in DCB‐based group vs. 17.9% in DES‐only group, p = 0.047). In the DCB‐based group, 59.0% of the patients (n = 23) underwent DCB‐only treatment. There were no cases of abrupt vessel closure requiring treatment following DCB application. The MACE were comparable between both groups (12.8% in DCB‐based group vs. 17.9% in DES‐only group, p = 0.861) after 2 years.Conclusions: In patients with unprotected LM true bifurcation lesions, DCB‐based treatment demonstrated comparable clinical outcomes at the 2‐year follow‐up when compared to DES‐only treatment. DCB‐based treatment could be considered a safe and effective alternative to DES for carefully selected patients who have achieved satisfactory predilation results (Impact of DCB Treatment in De Novo Coronary Lesion; NCT04619277).Keywords
This publication has 33 references indexed in Scilit:
- Clinical Impact of Drug-Coated Balloon–Based Percutaneous Coronary Intervention in Patients With Multivessel Coronary Artery DiseaseJACC: Cardiovascular Interventions, 2023
- Percutaneous Coronary Intervention for Left Main Coronary Artery DiseaseJACC: Asia, 2022
- Percutaneous treatment of left main chronic total occlusion with paclitaxel-coated balloonEuropean Heart Journal - Case Reports, 2021
- Efficacy of drug‐coated balloon angioplasty after directional coronary atherectomy for coronary bifurcation lesions (DCA/DCB registry)Catheterization and Cardiovascular Interventions, 2020
- Clinical Outcomes Following Coronary Bifurcation PCI TechniquesJACC: Cardiovascular Interventions, 2020
- Drug-Coated Balloons for Coronary Artery DiseaseJACC: Cardiovascular Interventions, 2020
- 3-Year Outcomes of the DKCRUSH-V Trial Comparing DK Crush With Provisional Stenting for Left Main Bifurcation LesionsJACC: Cardiovascular Interventions, 2019
- Pathophysiology of native coronary, vein graft, and in-stent atherosclerosisNature Reviews Cardiology, 2015
- Differential Prognostic Effect Between First- and Second-Generation Drug-Eluting Stents in Coronary Bifurcation LesionsJACC: Cardiovascular Interventions, 2015
- Late Thrombosis After Double Versus Single Drug-Eluting Stent in the Treatment of Coronary BifurcationsJACC: Cardiovascular Interventions, 2013